Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$9.48 -0.9%	$8.51	$4.00 ▼ $14.44	$809.31M	0.68	1.18 million shs	2.82 million shs
CPRX Catalyst Pharmaceuticals	$21.78 -0.5%	$23.87	$14.97 ▼ $26.58	$2.66B	0.72	1.11 million shs	2.41 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
PTGX Protagonist Therapeutics	$55.69 +0.9%	$48.78	$32.50 ▼ $60.60	$3.45B	2.25	887,934 shs	1.55 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	0.00%	+4.29%	+25.90%	+10.49%	+124.64%
CPRX Catalyst Pharmaceuticals	0.00%	-3.11%	-12.49%	-10.19%	+40.61%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	+4.18%
PTGX Protagonist Therapeutics	0.00%	+4.41%	+17.79%	+15.16%	+60.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.8458 of 5 stars	3.7	0.0	0.0	4.7	2.9	0.8	0.6
CPRX Catalyst Pharmaceuticals	4.9201 of 5 stars	3.6	1.0	0.0	3.9	3.4	3.3	3.8
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	1.0308 of 5 stars	2.5	1.0	0.0	0.0	1.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	364.14% Upside
CPRX Catalyst Pharmaceuticals	3.25	Buy	$32.83	50.75% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	18.69% Upside

Current Analyst Ratings Breakdown

Latest AVXL, CPRX, MOR, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
5/19/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/10/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/7/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/7/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/31/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CPRX Catalyst Pharmaceuticals	$491.73M	5.40	$2.45 per share	8.90	$6.10 per share	3.57
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
PTGX Protagonist Therapeutics	$434.43M	7.95	$4.52 per share	12.33	$11.33 per share	4.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-40.93%	-36.38%	8/5/2025 (Estimated)
CPRX Catalyst Pharmaceuticals	$163.89M	$1.57	13.87	10.23	0.89	36.91%	42.45%	36.59%	8/6/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
PTGX Protagonist Therapeutics	$275.19M	$0.75	74.25	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)

Latest AVXL, CPRX, MOR, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	6.74	6.74
CPRX Catalyst Pharmaceuticals	N/A	6.14	5.96
MOR MorphoSys	4.98	1.38	1.38
PTGX Protagonist Therapeutics	N/A	17.25	17.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
CPRX Catalyst Pharmaceuticals	79.22%
MOR MorphoSys	18.38%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.00%
CPRX Catalyst Pharmaceuticals	10.40%
MOR MorphoSys	0.05%
PTGX Protagonist Therapeutics	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.98 million	Optionable
CPRX Catalyst Pharmaceuticals	80	121.97 million	109.29 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable

AVXL, CPRX, MOR, and PTGX Headlines

Recent News About These Companies

PTGX Protagonist Therapeutics, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

June 26, 2025 | accessnewswire.comA

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera

June 24, 2025 | msn.com

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth

June 20, 2025 | investing.com

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

June 20, 2025 | msn.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Lifted by Exchange Traded Concepts LLC

June 19, 2025 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Citigroup

June 17, 2025 | marketbeat.com

Assenagon Asset Management S.A. Sells 7,367 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 17, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from Brokerages

June 14, 2025 | marketbeat.com

GAMMA Investing LLC Raises Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 13, 2025 | marketbeat.com

Arturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock

June 12, 2025 | insidertrades.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 10,000 Shares

June 11, 2025 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Hold" at Wall Street Zen

June 8, 2025 | marketbeat.com

Hennion & Walsh Asset Management Inc. Sells 6,008 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 7, 2025 | marketbeat.com

Short Interest in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Decreases By 13.6%

June 5, 2025 | marketbeat.com

9 Analysts Assess Protagonist Therapeutics: What You Need To Know

June 4, 2025 | benzinga.com

Protagonist Therapeutics' (PTGX) "Buy" Rating Reaffirmed at HC Wainwright

June 3, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stake Lifted by Mackenzie Financial Corp

June 2, 2025 | marketbeat.com

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

June 1, 2025 | businesswire.com

Wellington Management Group LLP Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 1, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $11.11 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Stocks Set to Double—And There's Still Time to Buy
By Nathan Reiff | June 12, 2025
View 3 Stocks Set to Double—And There's Still Time to Buy
More Than a Monetary Metal: Silver's Case for Outperformance
By Jeffrey Neal Johnson | June 22, 2025
View More Than a Monetary Metal: Silver's Case for Outperformance
3 Stocks Hitting All-Time Highs With More Room to Run
By Dan Schmidt | June 27, 2025
View 3 Stocks Hitting All-Time Highs With More Room to Run
Why Hims & Hers Stock Could Be a Multi-Bagger in the Making
By Gabriel Osorio-Mazilli | June 24, 2025
View Why Hims & Hers Stock Could Be a Multi-Bagger in the Making
Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming
By Thomas Hughes | June 26, 2025
View Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming

AVXL, CPRX, MOR, and PTGX Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$9.48 -0.09 (-0.94%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.30 -0.18 (-1.90%)

As of 04:52 AM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Catalyst Pharmaceuticals NASDAQ:CPRX

$21.78 -0.11 (-0.50%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$22.00 +0.22 (+1.01%)

As of 04:23 AM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 06/27/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Protagonist Therapeutics NASDAQ:PTGX

$55.69 +0.47 (+0.85%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$56.00 +0.31 (+0.56%)

As of 04:37 AM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time